NO930514L - Hemming av influensavirus type a, ann arbor-stamme h2n2 med antisenseoligonukleotider - Google Patents
Hemming av influensavirus type a, ann arbor-stamme h2n2 med antisenseoligonukleotiderInfo
- Publication number
- NO930514L NO930514L NO93930514A NO930514A NO930514L NO 930514 L NO930514 L NO 930514L NO 93930514 A NO93930514 A NO 93930514A NO 930514 A NO930514 A NO 930514A NO 930514 L NO930514 L NO 930514L
- Authority
- NO
- Norway
- Prior art keywords
- influenza virus
- oligonucleotides
- inhibition
- preferred embodiments
- antisense oligonucleotides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/11—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/13—Decoys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3527—Other alkyl chain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Abstract
Sammensetninger og metoder for behandling og diagnose av Influensa A-, B- eller C-lnfeksJoner. I henhold til foretrukkede utførelsesformer blir det skaffet til veie oligonukleotider eller oligonukleotidanaloger som er spesifikke komplementære med H2N2 viral RNA. I andre foretrukkede utførelsesformer er oligonukleotidene spesifikk komplementære med et transkripsjonsinltieringssete, et translasjonslnitieringssete, 5'- utranslaterte sekvenser, 3'-utranslaterte sekvenser og intron/exon-forbindelse til Influensavirus mRNA. I ytterligere foretrukkede utførelsesformer er oligo- nukleotldene spesifikke komplementære med RNA-sekvenser som involvert l splelslng av vlral RNA eller viral- pakking. Fremgangsmåter for å behandle dyr som lider av influensavirus A-, B- eller C-infeksJoner er også beskrevet.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56728790A | 1990-08-14 | 1990-08-14 | |
PCT/US1991/005742 WO1992003454A1 (en) | 1990-08-14 | 1991-08-13 | Inhibition of influenza virus type a, ann arbor strain h2n2 by antisense oligonucleotides |
Publications (2)
Publication Number | Publication Date |
---|---|
NO930514D0 NO930514D0 (no) | 1993-02-12 |
NO930514L true NO930514L (no) | 1993-04-02 |
Family
ID=24266540
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO93930514A NO930514L (no) | 1990-08-14 | 1993-02-12 | Hemming av influensavirus type a, ann arbor-stamme h2n2 med antisenseoligonukleotider |
Country Status (11)
Country | Link |
---|---|
US (1) | US5580767A (no) |
EP (1) | EP0543938A4 (no) |
JP (1) | JPH06501843A (no) |
KR (1) | KR970005274B1 (no) |
AU (1) | AU652577B2 (no) |
BR (1) | BR9106747A (no) |
CA (1) | CA2089562A1 (no) |
FI (1) | FI930628A (no) |
HU (1) | HUT69956A (no) |
NO (1) | NO930514L (no) |
WO (1) | WO1992003454A1 (no) |
Families Citing this family (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7119184B2 (en) * | 1991-08-12 | 2006-10-10 | Isis Pharmaceuticals, Inc. | Oligonucleotides having A-DNA form and B-DNA form conformational geometry |
US6369209B1 (en) | 1999-05-03 | 2002-04-09 | Isis Pharmaceuticals, Inc. | Oligonucleotides having A-DNA form and B-DNA form conformational geometry |
US5523389A (en) * | 1992-09-29 | 1996-06-04 | Isis Pharmaceuticals, Inc. | Inhibitors of human immunodeficiency virus |
GB2273932A (en) * | 1992-11-24 | 1994-07-06 | Stiefel Laboratories | Stable oligonucleotides |
CN1124980A (zh) * | 1993-03-31 | 1996-06-19 | 海布里顿公司 | 具有改良抗流感活性的经修饰寡核苷酸 |
US6576752B1 (en) | 1997-02-14 | 2003-06-10 | Isis Pharmaceuticals, Inc. | Aminooxy functionalized oligomers |
US6172209B1 (en) | 1997-02-14 | 2001-01-09 | Isis Pharmaceuticals Inc. | Aminooxy-modified oligonucleotides and methods for making same |
US6127533A (en) * | 1997-02-14 | 2000-10-03 | Isis Pharmaceuticals, Inc. | 2'-O-aminooxy-modified oligonucleotides |
WO1999006068A2 (en) | 1997-07-31 | 1999-02-11 | Hawaii Biotechnology Group, Inc. | Recombinant dimeric envelope vaccine against flaviviral infection |
CA2513336A1 (en) * | 1998-03-20 | 1999-09-30 | Benitec Australia Ltd. | Control of gene expression in a non-human eukaryotic cell, tissue or organ |
AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
US6841539B1 (en) | 1998-05-21 | 2005-01-11 | Isis Pharmaceuticals, Inc. | Compositions and methods for topical delivery of oligonucleotides |
US6277967B1 (en) | 1998-07-14 | 2001-08-21 | Isis Pharmaceuticals, Inc. | Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages |
US6867294B1 (en) * | 1998-07-14 | 2005-03-15 | Isis Pharmaceuticals, Inc. | Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages |
US6242589B1 (en) | 1998-07-14 | 2001-06-05 | Isis Pharmaceuticals, Inc. | Phosphorothioate oligonucleotides having modified internucleoside linkages |
US6335194B1 (en) | 1998-09-29 | 2002-01-01 | Isis Pharmaceuticals, Inc. | Antisense modulation of survivin expression |
US6077709A (en) | 1998-09-29 | 2000-06-20 | Isis Pharmaceuticals Inc. | Antisense modulation of Survivin expression |
RU2233844C2 (ru) | 1999-02-12 | 2004-08-10 | Санкио Компани Лимитед | Новые нуклеозидные и олигонуклеотидные аналоги |
JP4151751B2 (ja) * | 1999-07-22 | 2008-09-17 | 第一三共株式会社 | 新規ビシクロヌクレオシド類縁体 |
US6423885B1 (en) | 1999-08-13 | 2002-07-23 | Commonwealth Scientific And Industrial Research Organization (Csiro) | Methods for obtaining modified phenotypes in plant cells |
US6147200A (en) * | 1999-08-19 | 2000-11-14 | Isis Pharmaceuticals, Inc. | 2'-O-acetamido modified monomers and oligomers |
US6544958B2 (en) * | 2001-03-26 | 2003-04-08 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Of Her Majesty's Canadian Government | Therapy of respiratory influenza virus infection using free and liposome-encapsulated ribonucleotides |
US7420028B2 (en) * | 2001-03-27 | 2008-09-02 | Samuel Bogoch | Replikins and methods of identifying replikin-containing sequences |
NZ592340A (en) * | 2001-03-27 | 2012-12-21 | Elenore S Bogoch | A method for making a virus vaccine compising Replikin peptides |
US7452963B2 (en) * | 2001-03-27 | 2008-11-18 | Samuel Bogoch | Replikin peptides and antibodies therefore |
US7189800B2 (en) * | 2001-03-27 | 2007-03-13 | Samuel Bogoch | Replikin peptides in rapid replication of glioma cells and in influenza epidemics |
US20060160759A1 (en) * | 2002-09-28 | 2006-07-20 | Jianzhu Chen | Influenza therapeutic |
US20040242518A1 (en) * | 2002-09-28 | 2004-12-02 | Massachusetts Institute Of Technology | Influenza therapeutic |
US7807801B2 (en) * | 2003-08-05 | 2010-10-05 | Avi Biopharma Inc. | Oligonucleotide analog and method for treating flavivirus infections |
US20080311556A1 (en) * | 2003-08-07 | 2008-12-18 | Iversen Patrick L | Sense Antiviral Compound and Method for Treating Ssrna Viral Infection |
US20050222068A1 (en) * | 2003-10-23 | 2005-10-06 | Mourich Dan V | Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells |
EP1713332A4 (en) * | 2004-01-23 | 2010-08-18 | Avi Biopharma Inc | ANTISENSE OLIGOMERS AND METHOD FOR INDUCTION OF IMMUNOTHERAPY AND IMMUNOSUPPRESSION |
KR101147147B1 (ko) | 2004-04-01 | 2012-05-25 | 머크 샤프 앤드 돔 코포레이션 | Rna 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드 |
CA2875436A1 (en) | 2004-07-02 | 2006-08-17 | Sarepta Therapeutics, Inc. | Antisense antibacterial method and compound |
US8129352B2 (en) * | 2004-09-16 | 2012-03-06 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating ssRNA viral infection |
US8357664B2 (en) * | 2004-10-26 | 2013-01-22 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
US7524829B2 (en) * | 2004-11-01 | 2009-04-28 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
US7923207B2 (en) | 2004-11-22 | 2011-04-12 | Dharmacon, Inc. | Apparatus and system having dry gene silencing pools |
US7935811B2 (en) | 2004-11-22 | 2011-05-03 | Dharmacon, Inc. | Apparatus and system having dry gene silencing compositions |
US20060166234A1 (en) | 2004-11-22 | 2006-07-27 | Barbara Robertson | Apparatus and system having dry control gene silencing compositions |
US20060240032A1 (en) * | 2005-03-31 | 2006-10-26 | Hinrichs David J | Immunomodulating compositions and methods for use in the treatment of human autoimmune diseases |
US20090203055A1 (en) * | 2005-04-18 | 2009-08-13 | Massachusetts Institute Of Technology | Compositions and methods for RNA interference with sialidase expression and uses thereof |
US20060293268A1 (en) * | 2005-05-05 | 2006-12-28 | Rieder Aida E | Antisense antiviral compounds and methods for treating foot and mouth disease |
US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
US7790694B2 (en) * | 2005-07-13 | 2010-09-07 | Avi Biopharma Inc. | Antisense antibacterial method and compound |
US8524676B2 (en) * | 2005-09-08 | 2013-09-03 | Sarepta Therapeutics, Inc. | Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds |
AU2006287530A1 (en) * | 2005-09-08 | 2007-03-15 | Sarepta Therapeutics, Inc. | Antisense antiviral compound and method for treating picornavirus infection |
US20070197460A1 (en) * | 2005-11-01 | 2007-08-23 | Alnylam Pharmaceuticals, Inc. | Rnai inhibition of influenza virus replication |
US8501704B2 (en) * | 2005-11-08 | 2013-08-06 | Sarepta Therapeutics, Inc. | Immunosuppression compound and treatment method |
EP2002018B1 (en) * | 2006-03-07 | 2010-05-12 | AVI BioPharm, Inc. | Antisense antiviral compound and method for treating arenavirus infection |
LT2024499T (lt) * | 2006-05-10 | 2018-02-26 | Sarepta Therapeutics, Inc. | Oligonukleotido analogai, turintys katijonines jungtis tarp subvienetų |
US8785407B2 (en) * | 2006-05-10 | 2014-07-22 | Sarepta Therapeutics, Inc. | Antisense antiviral agent and method for treating ssRNA viral infection |
WO2008017473A2 (en) | 2006-08-08 | 2008-02-14 | Gunther Hartmann | Structure and use of 5' phosphate oligonucleotides |
US9481912B2 (en) | 2006-09-12 | 2016-11-01 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and identifying nucleic acid sequences in biological samples |
US8080645B2 (en) | 2007-10-01 | 2011-12-20 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection/transport compositions and methods |
US8097419B2 (en) | 2006-09-12 | 2012-01-17 | Longhorn Vaccines & Diagnostics Llc | Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009 |
US9598462B2 (en) | 2012-01-26 | 2017-03-21 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
US8809514B2 (en) | 2006-09-22 | 2014-08-19 | Ge Healthcare Dharmacon, Inc. | Tripartite oligonucleotide complexes and methods for gene silencing by RNA interference |
EP2121011B1 (en) * | 2006-12-06 | 2014-05-21 | Novartis AG | Vaccines including antigen from four strains of influenza virus |
US11041215B2 (en) | 2007-08-24 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | PCR ready compositions and methods for detecting and identifying nucleic acid sequences |
US9683256B2 (en) | 2007-10-01 | 2017-06-20 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system |
US10004799B2 (en) | 2007-08-27 | 2018-06-26 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
EP2772267B1 (en) | 2007-08-27 | 2016-04-27 | Longhorn Vaccines and Diagnostics, LLC | Immunogenic compositions and methods |
CA2861667C (en) | 2007-10-01 | 2017-06-13 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system and methods of use |
US11041216B2 (en) | 2007-10-01 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples |
US8188060B2 (en) | 2008-02-11 | 2012-05-29 | Dharmacon, Inc. | Duplex oligonucleotides with enhanced functionality in gene regulation |
EP2297323A1 (en) * | 2008-05-21 | 2011-03-23 | Hartmann, Gunther | 5' triphosphate oligonucleotide with blunt end and uses thereof |
US8034922B2 (en) * | 2008-08-22 | 2011-10-11 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for modulating activity of capped small RNAs |
WO2010080554A1 (en) * | 2008-12-17 | 2010-07-15 | Avi Biopharma, Inc. | Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis |
DK2396032T3 (en) | 2009-02-10 | 2016-12-19 | Seqirus Uk Ltd | Influenza vaccines with reduced amounts of squalene |
KR101944119B1 (ko) * | 2009-11-13 | 2019-01-30 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 안티센스 항바이러스 화합물 및 인플루엔자 바이러스 감염을 치료하는 방법 |
KR102095478B1 (ko) | 2010-05-28 | 2020-04-01 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체 |
US8198429B2 (en) | 2010-08-09 | 2012-06-12 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
US10017763B2 (en) | 2010-09-03 | 2018-07-10 | Sarepta Therapeutics, Inc. | dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups |
EP2508530A1 (en) | 2011-03-28 | 2012-10-10 | Rheinische Friedrich-Wilhelms-Universität Bonn | Purification of triphosphorylated oligonucleotides using capture tags |
WO2013067873A1 (zh) * | 2011-11-09 | 2013-05-16 | 南京森楠生物技术研究有限公司 | 抗流行性感冒病毒的核酸、肽核酸及其制剂 |
CA2854907C (en) | 2011-11-18 | 2020-03-10 | Sarepta Therapeutics, Inc. | Functionally-modified oligonucleotides and subunits thereof |
EP2712870A1 (en) | 2012-09-27 | 2014-04-02 | Rheinische Friedrich-Wilhelms-Universität Bonn | Novel RIG-I ligands and methods for producing them |
US10378017B2 (en) | 2013-12-02 | 2019-08-13 | Brandeis University | High temperature selection of nucleotide-supported carbohydrate vaccines and resulting glycosylated oligonucleotides |
CA2985652C (en) | 2015-05-14 | 2020-03-10 | Gerald W. FISHER | Rapid methods for the extraction of nucleic acids from biological samples |
US11020417B2 (en) | 2015-06-04 | 2021-06-01 | Sarepta Therapeutics, Inc | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
CN108778344A (zh) | 2016-03-02 | 2018-11-09 | 里兰斯坦福初级大学理事会 | 抗流感病毒的泛基因型药剂和其使用方法 |
US11339392B2 (en) | 2016-03-02 | 2022-05-24 | The Board Of Trustees Of The Leland Stanford Junior University | Pan-genotypic agents against influenza virus and methods of using the same |
US11046958B2 (en) | 2017-01-24 | 2021-06-29 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Antisense oligonucleotides that inhibit influenza virus replication and uses thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0081099A3 (en) * | 1981-12-04 | 1983-08-10 | Sloan-Kettering Institute For Cancer Research | Capped oligonucleotide anti-viral agents |
NZ209840A (en) * | 1983-10-17 | 1988-11-29 | Kaji Akira | A method of inhibiting viral propagation by hybridising dna with the viral rna thus blocking its action |
US5190931A (en) * | 1983-10-20 | 1993-03-02 | The Research Foundation Of State University Of New York | Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA |
FR2568254B1 (fr) * | 1984-07-25 | 1988-04-29 | Centre Nat Rech Scient | Application d'oligonucleotides lies a un agent intercalant, notamment a titre de medicament |
US5194428A (en) * | 1986-05-23 | 1993-03-16 | Worcester Foundation For Experimental Biology | Inhibition of influenza virus replication by oligonucleotide phosphorothioates |
US5004810A (en) * | 1988-09-30 | 1991-04-02 | Schering Corporation | Antiviral oligomers |
US5166057A (en) * | 1989-08-28 | 1992-11-24 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant negative strand rna virus expression-systems |
DE3929144A1 (de) * | 1989-09-02 | 1991-03-07 | Behringwerke Ag | Nachweis von influenza-a-virus durch polymerase-kettenreaktion (pcr) nach reverser transkription eines bereichs des viralen haemagglutinin-gens |
US5166195A (en) * | 1990-05-11 | 1992-11-24 | Isis Pharmaceuticals, Inc. | Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides |
-
1991
- 1991-08-13 AU AU85360/91A patent/AU652577B2/en not_active Ceased
- 1991-08-13 WO PCT/US1991/005742 patent/WO1992003454A1/en not_active Application Discontinuation
- 1991-08-13 CA CA002089562A patent/CA2089562A1/en not_active Abandoned
- 1991-08-13 HU HU9300364A patent/HUT69956A/hu unknown
- 1991-08-13 US US07/955,718 patent/US5580767A/en not_active Expired - Lifetime
- 1991-08-13 BR BR919106747A patent/BR9106747A/pt not_active Application Discontinuation
- 1991-08-13 KR KR1019930700440A patent/KR970005274B1/ko not_active IP Right Cessation
- 1991-08-13 EP EP19910916802 patent/EP0543938A4/en not_active Ceased
- 1991-08-13 JP JP3515319A patent/JPH06501843A/ja active Pending
-
1993
- 1993-02-12 FI FI930628A patent/FI930628A/fi not_active Application Discontinuation
- 1993-02-12 NO NO93930514A patent/NO930514L/no unknown
Also Published As
Publication number | Publication date |
---|---|
WO1992003454A1 (en) | 1992-03-05 |
EP0543938A1 (en) | 1993-06-02 |
EP0543938A4 (en) | 1993-11-10 |
KR970005274B1 (ko) | 1997-04-15 |
AU8536091A (en) | 1992-03-17 |
JPH06501843A (ja) | 1994-03-03 |
FI930628A (fi) | 1993-03-24 |
HUT69956A (en) | 1995-09-28 |
US5580767A (en) | 1996-12-03 |
BR9106747A (pt) | 1993-07-20 |
FI930628A0 (fi) | 1993-02-12 |
AU652577B2 (en) | 1994-09-01 |
HU9300364D0 (en) | 1993-05-28 |
CA2089562A1 (en) | 1992-02-15 |
KR930701466A (ko) | 1993-06-11 |
NO930514D0 (no) | 1993-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO930514L (no) | Hemming av influensavirus type a, ann arbor-stamme h2n2 med antisenseoligonukleotider | |
McShan et al. | Inhibition of transcription of HIV-1 in infected human cells by oligodeoxynucleotides designed to form DNA triple helices. | |
DE69330372D1 (de) | ZUSAMMENSETZUNGEN UND VERFAHREN FüR DIE BEHANDLUNG VON MIT HEPATITIS C VIREN ASSOZIIERTEN KRANKHEITEN | |
Wu et al. | Purification of the human immunodeficiency virus type 1 enhancer and TAR binding proteins EBP‐1 and UBP‐1. | |
Wickstrom et al. | Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA. | |
ATE289519T1 (de) | Zusammensetzungen und verfahren zur behandlung von hepatitis c virus-bedingten erkrankungen | |
ATE153699T1 (de) | Therapeutische zusammensetzungen auf der basis von ribozymen | |
DE3876125T2 (de) | Behandlung der menschlichen viralinfektion durch doppelstrang-rna, kombiniert mit viralen inhibitoren. | |
PT966447E (pt) | Moleculas pequenas uteis no tratamento de doencas inflamatorias | |
ATE202140T1 (de) | Hemmung der neovaskulasierung durch vegf- spezifische oligonukleotide | |
DE69909775D1 (de) | Neue fettanaloge zur behandlung von diabetes | |
NO20013881D0 (no) | Fremstilling av iodixanol | |
ATE317432T1 (de) | Hiv-spezifische oligonukleotide und verfahren zu deren verwendung | |
DE69626393D1 (de) | Spezifische oligonukleotide für hepatitis b virus | |
OA08652A (fr) | Compositions, vaccin et anticorps monoclonaux utiles pour le traitement des affections par le virus HIV et procédés de production de ces anticorps et de diagnostic de la présence de ce virus. | |
Nakashima et al. | Proximity of mRNA5′-region and 18S rRNA in eukaryotic initiation complexes | |
DE60039601D1 (de) | Antisense gegen c-myc zur behandlung von polyzystischer nierenkrankheit | |
KR970703355A (ko) | 항-사이토메갈로바이러스 활성을 가진 올리고누클레오티드(oligonucleotides with anti-cytomegalovirus activity) | |
DK1237562T3 (da) | Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme | |
DE60041246D1 (de) | Hemmung der bildung von atherosklerotischen wunden mittels afabp antisens nukleinsäuren | |
WO1997046673A3 (en) | Inhibition of hiv-1 replication by antisense rna expression | |
Pfeifer et al. | Formation of a small ribonucleoprotein particle between Tat protein and trans-acting response element in human immunodeficiency virus-infected cells | |
HUP0100612A2 (hu) | Gyógyászati hatóanyagok szkrínelésére alkalmas eljárás | |
Fukuda et al. | Increase in nitric oxide synthase and cyclic GMP in vascular smooth muscle cells by treatment with aqueous extracts of Astragali Radix, Ginsen radix and Scutellariae radix | |
Sargan et al. | A temporal study of RNAs produced in maedi-visna virus infection of choroid plexus cells |